Cannabis and Hemp Industry Investment News

Cannabis Industry Press Releases and News Articles from the best investment journalist in the industry. Stay updated on all cannabis investment news from every online source, on MjInvest.com

EXMceuticals secures $2.3M in financing as cannabis producer responds to coronavirus pandemic

The  Vancouver-based company said it will focus efforts on the establishment and expansion of its Portuguese and European operations

The loan agreement with various arms-length parties will be used for general working capital purpose

Inc () announced Wednesday it has struck loan agreements to provide it with up to $2,356,000 in financing as the cannabis producer responds to the coronavirus (COVID19) pandemic.

The company said the loan agreements with various arms-length parties will be used for general working capital purposes. The loan is repayable within 18 months and bears an interest rate of 12% per annum, Also, the company has agreed to issue to the lenders' common shares equal in value to 20% at a price of $0.50 apiece. 

In a statement, EXMceuticals said: “Our operation has moved quickly to protect our staff and make sure their families are safe. We have also taken several proactive measures to preserve and maximize working capital while keeping operations as active as possible by having our teams work from home. We are committed to managing working capital and will adjust our plans as necessary.”

READ: EXMceuticals in the final stages of planning for an industrial-scale cannabis extraction facility in Portugal

The Vancouver-based company said its board has agreed to focus company efforts on the further establishment and expansion of its Portuguese and European operations, namely the planned refinery south of Lisbon.

Continue reading
  5 Hits

Lexaria Bioscience widens scope of pharmaceutical subsidiary in bid to develop treatment for coronavirus

Lexaria Pharmaceutical will look at how DehydraTECH could improve delivery and effectiveness of antiviral drugs to treat coronavirus

Researchers are looking at various antiviral drugs as potential candidates to treat infected patients

Lexaria Bioscience Corp () (OTCMKTS:LXRP) told investors Monday that it has broadened the scope of its pharmaceutical subsidiary in a bid to help assist in the global fight against coronavirus.

The company’s subsidiary Lexaria Pharmaceutical Corp will look at how the parent company’s DehydraTECH drug delivery platform could improve delivery and effectiveness of antiviral drugs to treat coronavirus.

Kelowna, British Columbia-based Lexaria said it plans to expand collaboration with leading laboratories in North America and internationally “as soon as possible.”

READ: Lexaria Bioscience initiates coronavirus drug delivery program

The news comes after the company revealed last week that it has initiated a program with top labs in the United States and Canada to study the benefits of the company’s DehydraTECH drug delivery platform for boosting the delivery and effectiveness of certain antiretroviral drugs being tapped in the fight against the coronavirus.

Continue reading
  11 Hits

Lexaria Bio Science working with frontline companies to battle COVID-19

viewLexaria Bioscience Corp.

Lexaria Bioscience (CSE:LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive in Vancouver to discuss the company commencing a program, in collaboration with leading laboratories in Canada and the U.S. to study the benefits of DehydraTECH  in the fight against coronavirus disease COVID-19.

Bunka telling Proactive about that technology and why it may be effective, in the way it delivers fat-soluble drugs into the bloodstream.

CSE:LXX

Market: CSE
Market Cap: $33.9 m
Follow

View company profile

Continue reading
  15 Hits

Lexaria Bioscience initiates coronavirus drug delivery program

The program will study the benefits of its DehydraTECH technology for boosting the delivery and effectiveness of fat-soluble antiretroviral drugs

Lexaria intends to conduct the study at a leading Canadian University where a study design and plan have already been submitted for ethics board approval

Lexaria Bioscience Corp (OTCMKTS:LXRP) (), a specialist in drug delivery technology, revealed Thursday that it has initiated a program with top labs in the United States and Canada to study the benefits of the company’s DehydraTECH drug delivery platform for boosting the delivery and effectiveness of certain antiretroviral drugs being tapped in the fight against the coronavirus (COVID-19).

Researchers are currently investigating different antiretroviral drugs as potential candidates to combat the disease.

“Many of these are fat-soluble and present significant bioavailability challenges in successfully reaching the human bloodstream when administered in oral form,” the Kelowna, British Columbia-based company — which is an established leader in oral delivery of fat-soluble drugs — noted in a statement.

According to a medical journal, Lexaria's patented DehydraTECH technology delivers fat-soluble drugs with increases of up to 317% more drug quantified in the blood in a human clinical study within the first 30 minutes of dosing relative to concentration matched controls.

Continue reading
  16 Hits

Medlab launches online clinical service for consultations with doctors

Medlab has developed the virtual clinic so that anyone can have access to a free, no-obligation, 10-minute confidential consultation via any computer or smart device with internet access.

Clinic appointments are available online

() has launched telehealth initiatives to minimise the potential impact of the COVID-19 virus.

It is a unique, online clinical service that offers advice and connects the Australian public to doctors, specialists, naturopaths and pharmacists.

Using disruptive technology, ‘the Clinic’ offers free 10-minute consultations via online bookings and video conferencing and can be accessed via https://clinic.medlab.co.

Smartphone scheduling

Medlab understands that people are time-poor, in remote locations or simply not always able to visit their healthcare practitioner but have access to digital technology.

Continue reading
  19 Hits

Canntab Therapeutics secures final tranche of C$3.7M private placement

The last tranche raised C$645,000 by offering nearly 1.3 million units at a price of $0.50 per unit

Canntab has filed 13 patents in Canada and the US that cover processes and formulations needed to create the its hard pill formulations

Canntab Therapeutics Limited () (OTCMKTS:CTABF), a biopharmaceutical company focused on hard pill cannabinoid formulations, has closed the final $645,000 tranche of its previously-announced C$3.7 million private placement.

The last tranche consisted of nearly 1.3 million units — each containing one share and one share purchase warrant — at a price of C$0.50 per unit. All told, the private placement consisted of 7.4 million units.

The warrants can be used to acquire an additional share at a price of C$0.75 for the next two years.

READ: Canntab Therapeutics nominates Canadian pharmaceutical executive Larry Latowsky as executive chairman

"With the gross proceeds from this financing we now have the capital to completely implement our business plan,” Canntab CFO Richard Goldstein said in a statement.

Continue reading
  22 Hits

Medlab Clinical shares surge on "primary evidence" of NanaBis™ cancer trial success

The strong results allow Medlab to focus on phase three designs specifically in the patient group with metastatic bone pain where breast or prostate are the primary cancers.

NanaBis™ could be an alternative analgesic medication for cancer patients

() has received independent review results for the NanaBis™ advanced cancer pain trial confirming that it was safe, tolerable and provided a major benefit in managing pain associated with metastatic cancers.

These results from an independent reviewer for the trial conducted at Royal North Shore Hospital in Sydney saw the company's share price increase 24% in early trade to an intra-day high of 28 cents.

The clinical trial was a single ascending dose (SAD), multiple ascending dose (MAD) investigation into pain management of patients with metastatic cancers with the NanaBis™ blend of cannabidiol (CBD) and tetrahydrocannabinol (THC).

"Primary evidence"

Medlab chief executive officer Dr Sean Hall said: “With a strong trial design, that involved a professional and strong clinical trial team and collaborators, today we have primary evidence that NanaBis™ is safe, tolerable and provided a significant benefit in managing pain associated with metastatic cancers.”

Continue reading
  27 Hits

Canntab Therapeutics nominates Canadian pharmaceutical executive Larry Latowsky as executive chairman

The incoming chairman previously served as the CEO of Katz Group Canada, which owns and operated a network of leading pharmacies across Canada

The appointment is subject to Health Canada approval, of which Latowsky is in the process of obtaining

Canntab Therapeutics Limited () (OTCMKTS:CTABF) announced plans to appoint pharmaceutical executive Larry Latowsky to its board of directors.

Latowsky will take on the role of executive chairman of the cannabis pill manufacturer, it said in a statement Friday.

“Over the past several months as an advisor I have realized my decision to associate with the right company in this space has been confirmed,” Latowsky said in a statement.

READ: Canntab Therapeutics awarded processing and sales license from Health Canada

The incoming chairman previously served as the CEO of Katz Group Canada, which owns and operated a network of leading pharmacies across Canada.

Continue reading
  44 Hits

Medlab Clinical in trading halt ahead of NanaBis™ cancer trial results

The NanaBis™ study seeks to recruit 2,000 Australian patients via medical or hospital settings to provide intervention data over a 12-month period.

Medlab is developing protocols for a phase three trial in Australia and the US

() is in a trading halt pending an announcement on the release of results from the NanaBis™ advanced cancer pain trial conducted at Royal North Shore Hospital in Sydney, Australia.

The trading halt will remain in place until the beginning of ASX trade on Monday, March 9, 2020, or when an announcement is released to the market, whichever occurs earliest.

Shares in the company, which has a market cap of approximately $53.6 million, last traded at 22.5 cents.

NanaBis™ study launch 

Medlab officially launched the NanaBis™ observational study in February which aims to provide evidence that is based on real-world data for safety, tolerability, use and potential adverse events as well as potential impacts on the patient while being prescribed other medicines.

Continue reading
  35 Hits

Lexaria Bioscience produces first DehydraTECH-enabled CBD emulsion for licensed client

The super-concentrated DehydraTECH-enabled liquid nanoemulsion was shipped to the client's production facility for incorporation into its cold-brewed coffee production

DehydraTECH is able to mask unwanted tastes, improve onset speed and increase the bioavailability of active pharmaceutical ingredients

Lexaria Bioscience Corp (OTCMKTS:LXRP) () announced that it has successfully processed its first CBD nanoemulsion for one of its licensed clients using its DehydraTECH technology. 

The British Columbia company provides emulsion services using DehydraTECH to qualifying clients who want to formulate ready-to-drink beverages containing CBD. 

Super-concentrated DehydraTECH-enabled liquid nanoemulsion was shipped to the client's production facility for incorporation into its cold-brewed coffee production and bottling line. Lexaria said it was able to process nearly 100,000 20 mg servings of DehydraTECH-empowered CBD concentrate.

READ: Lexaria Bioscience explains benefit of its CBD infused powders against backdrop of consumer concerns on potency

The client expects to begin distribution of its CBD beverage line in US stores soon, the company said.

Continue reading
  30 Hits

Canntab Therapeutics raised 3 million dollars and receives final Health Canada Licence

viewCanntab Therapeutics Ltd

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive in Vancouver to discuss the major announcement from the company that they have received their key Heath Canada Licence that allows them Processing & Sales for Medical Purposes.

Goldstein also discussed how much money they were able to raise and why a certain consultant with the company will be key to their success going forward. 


 

CSE:PILL

Continue reading
  38 Hits

EXMceuticals says it's in the final stages of planning for an industrial-scale cannabis extraction facility in Portugal

The Vancouver-based company is building the operation to distribute medical cannabis ingredients for cannabis-based compounds and active pharmaceutical ingredients

The extraction company is also planning to import a sample of dried cannabis flowers from its Portuguese farming subsidiary for scientific purposes

Inc () told shareholders Tuesday that it is in the final stages of planning for an industrial-scale cannabis extraction facility in Portugal.

The Vancouver-based company is building the operation to distribute medical cannabis ingredients for cannabis-based compounds and active pharmaceutical ingredients.

It is “actively exploring” a memorandum of understanding with one of the largest North American producers of extracts to ensure the refinery will be operating at capacity when it opens its doors, the firm said in a release.

READ: EXMceuticals taps seasoned finance professional Michael Kinley as CFO

The extraction company is also planning to import a sample of dried cannabis flowers from its Portuguese farming subsidiary for scientific purposes. The first shipment will be transported to EXMceutical’s laboratory in Lisbon shortly.

Continue reading
  31 Hits

Canntab Therapeutics awarded processing and sales license from Health Canada

The company is getting ready to move into full-scale manufacturing of its cannabinoid pills

The company plans to roll out new brands and products for sale beginning in the summer

Canntab Therapeutics Limited () (OTCMKTS:CTABF) is getting ready to move into full-scale manufacturing of its cannabinoid pills after receiving its processing and sales license from Health Canada on Friday.

The Toronto-based company manufactures and distributes a suite of hard pill CBD formulations in multiple doses and time-release combinations.

Last week the firm received its research license from the Canadian regulator, allowing it to continue the research and development of its pharmaceutical-grade cannabis hard pill formulations at its Markham, Ontario facility. 

READ: Canntab awarded Health Canada cannabis research licence

"With the licensing and financing, we are now in a position to move into full scale manufacturing and distribution of our next generation of biopharmaceutical cannabinoid solutions,” said Canntab CEO Jeff Renwick.

Continue reading
  40 Hits

Canntab Therapeutics granted cannabis research licence from Health Canada

viewCanntab Therapeutics Ltd

Canntab Therapeutics Limited (CSE:PILL-OTCQB: CTABF) Co-Founder and CFO Richard Goldstein joined Steve Darling from Proactive Vancouver on Skype to discuss the company being granted their cannabis research license from Health Canada. Goldstein talks about what this license allows Canntab to do and what their next step is.

Goldstein also told Proactive what the company plan on for the remainder of 2020. 

CSE:PILL

Market: CSE
Market Cap: $12.65 m
Follow

View company profile

Continue reading
  48 Hits

Canntab awarded Health Canada cannabis research licence

It marks the final step to obtain a standard processing licence and sale for medical purposes licence

Canntab’s facility in Markham, Ontario, is equipped to accommodate all manufacturing necessary to produce its pharmaceutical-grade cannabis hard pill formulations

Canntab Therapeutics Limited () (OTCMKTS:CTABF) revealed Monday that Health Canada has granted it a cannabis research licence for continuing the research and development of its pharmaceutical-grade cannabis hard pill formulations at its Markham Ontario facility. 

In a statement, the Canadian company said that after getting a standard processing licence and sale for medical purposes licence from Health Canada, Canntab will begin full-scale manufacturing of its suite of precision oral dose products.

The firm is a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application. The company's hard pill oral delivery formulations encapsulate extended-release, instant release, and bi-layered hard pills which offer patients and practitioners accurate dosing.

READ: Canntab Therapeutics submits Site Evidence Package to Health Canada for Licence Producer Status approval

The additional licences will enable Canntab to submit a notice of new cannabis products (NNCP) to Health Canada, said the company.

Continue reading
  48 Hits

Medlab Clinical expanding cannabis-based medicines into Europe

By having a European subsidiary, Medlab can save on drug registration fees.

In Australia, Medlab has proceeded to stage II for its cannabis cancer trial

() has formally incorporated a wholly owned subsidiary MDC Europe Limited to facilitate expansion into Europe.

The subsidiary will be used specifically for current and future dealings regarding NanaBis™ and the proposed drug registration models as per the European Medicines Agency (EMA). 

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

European registration of NanaBis™ progressing

Meetings have been held with EMA on the pathway for registration of NanaBis™.

Continue reading
  37 Hits

Medlab Clinical progresses through trials, overseas registration process

Medlab Clinical () has completed the first stage medical trials of its NanaBis product, and is encouraged by its progress with US and European medical registration administrations.

CEO Sean Hall distinguishes Medlab Clinical () from other "pot stocks" through its focus on proven medical outcomes and its breadth of products.

Hall says the company has sizeable upside as potential applications for its product include not only pain treatments but also other chronic health issues such as Type II Diabetes and depression.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Continue reading
  37 Hits

Medlab Clinical substantial shareholder Farjoy lifts holding through on-market purchases

The Sydney-based investor has demonstrated confidence in the company’s medical research strategy.

Farjoy now holds almost 24 million shares, or 11.53%, of Medlab

() substantial shareholder Farjoy Pty Ltd has increased its holding in the company through a series of on-market purchases.

The Sydney-based investor now holds almost 24 million shares, or 11.53%, of Medlab, up from 10.51%.

Since 17 August 2018, Farjoy has acquired more than 2.123 million shares on-market at prices ranging from 34 cents to 43 cents.

The total value of these acquisitions is almost $840,000.

Continue reading
  34 Hits

Medlab Clinical proceeding to stage II for cannabis cancer trial

The company will now proceed with stage II of the human clinical trial.

Stage I findings showed that NanaBis™ is safe indications confirm it helps with pain reduction

() has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital.

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

Medlab has received formal approval from the appropriate authority to proceed to stage II of the human cancer trial. 

Stage II of the clinical trial will focus on further safety but also tolerance and dose escalation.

Continue reading
  37 Hits

Medlab's Hall: "Time to offer something new" to challenge reliance on opioids

's () Sean Hall tells Proactive that the company is building a cannabis-based drug that is the size of a nanoparticle.

Hall adds that the company is currently intent on marketing the product in around 18 countries, including the EU, the US, Canada, and Australia.

Hall also says that the firm is currently talking to several pharmaceutical firms, two of which are of "significant note".

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Continue reading
  31 Hits